<DOC>
	<DOC>NCT01844765</DOC>
	<brief_summary>To evaluate the safety, efficacy and concentration of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to &lt;18 years).</brief_summary>
	<brief_title>Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Neoplastic Processes</mesh_term>
	<criteria>Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib Karnofsky or Lansky ≥ 50 Adequate renal, hepatic and pancreatic function Potassium, magnesium, phosphorus and total calcium values ≥ LLN (lower limit of normal) Written informed consent Treatment with strong CYP3A4 inhibitors or inducers Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval Acute or chronic liver, pancreatic or severe renal disease History of pancreatitis or chronic pancreatitis. Impaired cardiac function No evidence of active graft vs host and &lt;3mo since Stem Cell Transplant Total body irradiation (TBI) or craniospinal radiation therapy &lt;6months Hypersensitivity to the active ingredient or any of the excipients including lactose. Other protocoldefined inclusion/exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tasigna</keyword>
	<keyword>nilotinib treatment</keyword>
	<keyword>chronic phase</keyword>
	<keyword>Ph+ CML</keyword>
	<keyword>accelerated phase</keyword>
	<keyword>newly diagnosed Ph+ CML</keyword>
	<keyword>pediatric</keyword>
	<keyword>24 month treatment</keyword>
</DOC>